BionTech

Key TakeawaysPfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine receives a positive recommendation from the European Medicines Agency. The vaccine targets multiple circulating Omicron...

Combination vaccine development by Pfizer and BioNTech has made significant strides, with the companies announcing key results from their Phase 3 clinical trial. The...

BioNTech has announced its decision to exit the joint development of their cancer programmed-cell death 1 ligand-1 (PD-L1) therapy, acasunlimab (BNT311/GEN1046), with Genmab. This...

As sales of COVID-19 vaccines continue to decline, lawsuits associated with these products are on the rise. In the latest legal action, the University...

BioNTech SE, a leading biopharmaceutical company, has announced positive topline data from its Phase 2 clinical trial evaluating the mRNA cancer immunotherapy BNT111 in...

Pfizer and BioNTech announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization...

As global efforts to advance next-generation vaccines in Africa continue, spearheaded by the World Health Organization (WHO) and the Bill & Melinda Gates Foundation,...

Starting in March, residents of Great Britain will have the unique opportunity to purchase the latest Omicron-specific Pfizer/BioNTech COVID-19 vaccine, known as Comirnaty, directly...

Pfizer and BioNTech have reported encouraging results from their Phase 1/2 clinical trial, which evaluated the safety, tolerability, and immunogenicity of mRNA-based combination vaccines...